惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

T
Tailwind CSS Blog
P
Proofpoint News Feed
V
Visual Studio Blog
H
Hackread – Cybersecurity News, Data Breaches, AI and More
爱范儿
爱范儿
Microsoft Azure Blog
Microsoft Azure Blog
Recent Announcements
Recent Announcements
Vercel News
Vercel News
Hugging Face - Blog
Hugging Face - Blog
GbyAI
GbyAI
博客园 - 聂微东
D
DataBreaches.Net
酷 壳 – CoolShell
酷 壳 – CoolShell
Microsoft Security Blog
Microsoft Security Blog
L
LangChain Blog
美团技术团队
H
Help Net Security
aimingoo的专栏
aimingoo的专栏
C
Check Point Blog
U
Unit 42
博客园 - 叶小钗
有赞技术团队
有赞技术团队
M
MIT News - Artificial intelligence
MongoDB | Blog
MongoDB | Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call T...
SA Transcripts · 2026-05-05 · via All Articles on Seeking Alpha

Q1: 2026-05-04 Earnings Summary

EPS of $0.05 beats by $0.11

 | 

Revenue of

$127.20M

(55.63% Y/Y)

misses by $9.58M

Travere Therapeutics, Inc. (TVTX) Q1 2026 Earnings Call May 4, 2026 4:30 PM EDT

Company Participants

Nivi Nehra - Vice President of Corporate Communications & Investor Relations
Eric Dube - President, CEO & Director
Jula Inrig - Chief Medical Officer
Peter Heerma - Chief Commercial Officer
Chris Cline - Chief Financial Officer
William Rote - Chief Research Officer

Conference Call Participants

Will Soghikian - Leerink Partners LLC, Research Division
Gregory Wiessner - TD Cowen, Research Division
Anupam Rama - JPMorgan Chase & Co, Research Division
Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division
Vamil Divan - Guggenheim Securities, LLC, Research Division
Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division
Sadia Rahman - Wells Fargo Securities, LLC, Research Division
Laura Chico - Wedbush Securities Inc., Research Division
Maurice Raycroft - Jefferies LLC, Research Division
Jason Zemansky - BofA Securities, Research Division
Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division

Presentation

Operator

Hello, and welcome to Travere Therapeutics First Quarter 2026 Financial Results Conference Call. Today's call is being recorded.

At this time, I would like to turn the conference call over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi.

Nivi Nehra
Vice President of Corporate Communications & Investor Relations

Thank you, operator. Good afternoon, and welcome to Travere Therapeutics First Quarter 2026 Financial Results and Corporate Update Call. Thank you all for joining.

Today's call will be led by Dr. Eric Dube, our President and Chief Executive Officer. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; Peter Heerma, our Chief Commercial Officer; and Chris Cline, our Chief Financial Officer. Dr. Bill Rote, our Chief Research Officer, will join us for the Q&A.

Before we begin, I'd like to remind everyone that statements made during this call regarding matters that are not historical facts are forward-looking statements within